Is Mereo BioPharma Group plc (MREO) a Buy, Sell, or Hold?
Mereo BioPharma Group plc
NASDAQ:MREO
$0.314 USD
-$0.01 (-2.18%)
- Volume
- 546.77K
- Average Volume
- 3.47M
- Market Capitalization
- $50.12M
- P/E Ratio
- -1.40
- Dividend Yield
- 0.00%
- Price Target
- $2.50
- Year High
- $2.37
- Year Low
- $0.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.48
| Source | Headline |
|---|---|
|
4basebio Announces Appointment of Chief Financial Officer and Board Changes
Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the appointment of Richard Bungay as Chief Financial Officer, with effect from July 2026. Richard takes over the role from David Roth, who stepped down from the Board earlier this year and remained working with the Company over the orderly handover period. globenewswire.com - 2026-05-14 07:00:00 |
|
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments. globenewswire.com - 2026-05-12 07:30:00 |
|
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments. globenewswire.com - 2026-05-12 07:30:00 |
